These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11121861)

  • 1. Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells.
    Ohta I; Gorai I; Miyamoto Y; Yang J; Zheng JH; Kawata N; Hirahara F; Shirotake S
    Cancer Lett; 2001 Jan; 162(1):39-48. PubMed ID: 11121861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
    Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
    Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of advanced ovarian clear cell adenocarcinoma responding to cisplatin-cyclophosphamide and paclitaxel-carboplatin].
    Iwasaki K; Komuro Y; Masumoto N; Asaoka K; Ishitani K
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1483-6. PubMed ID: 10500539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.
    Reed E; Kohn EC; Sarosy G; Dabholkar M; Davis P; Jacob J; Maher M
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):90-6. PubMed ID: 7541159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
    Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
    J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxane sensitivity of ovarian carcinoma in vitro.
    Engblom P; Rantanen V; Kulmala J; Heiskanen J; Grenman S
    Anticancer Res; 1997; 17(4A):2475-9. PubMed ID: 9252666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
    Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
    Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
    Chiba Y; Sato S; Itamochi H; Yoshino N; Fukagawa D; Kawamura H; Suga Y; Kojima-Chiba A; Muraki Y; Sugai T; Sugiyama T
    Int J Gynecol Cancer; 2017 Oct; 27(8):1666-1674. PubMed ID: 28786875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential high dose-density chemotherapy in advanced ovarian cancer.
    Tognoni A; Pronzato P; Cadenotti L; Ghio E; Manna N; Pensa F; Marino L
    Anticancer Res; 2000; 20(5C):3957-61. PubMed ID: 11268483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
    Crotzer DR; Sun CC; Coleman RL; Wolf JK; Levenback CF; Gershenson DM
    Gynecol Oncol; 2007 May; 105(2):404-8. PubMed ID: 17292461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
    PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties.
    Gorai I; Nakazawa T; Miyagi E; Hirahara F; Nagashima Y; Minaguchi H
    Gynecol Oncol; 1995 Apr; 57(1):33-46. PubMed ID: 7535723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma.
    Adachi S; Ogasawara T; Yamasaki N; Shibahara H; Kanazawa R; Tsuji Y; Takemura T; Koyama K
    Jpn J Clin Oncol; 1999 Sep; 29(9):434-7. PubMed ID: 10563197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, epirubicin, and ifosfamide versus cisplatin, epirubicin, and cyclophosphamide in clear cell carcinoma of the ovary.
    Nishida T; Sugiyama T; Yakushiji M
    Gynecol Oncol; 1997 Nov; 67(2):230. PubMed ID: 9367714
    [No Abstract]   [Full Text] [Related]  

  • 19. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.